New appointment at Pro-Pharmaceuticals
This article was originally published in Scrip
Pro-Pharmaceuticals (US) has named Dr Peter Traber acting chief medical officer. He will lead the Phase III colorectal cancer trial for the company's lead product candidate, Davanat, a polysaccharide polymer that targets Galectin receptors, as well as the overall US FDA approval process. Dr Traber, who has served as senior vice-president for clinical development and medical affairs and as chief medical officer at GlaxoSmithKline, was elected to Pro-Pharmaceuticals' board of directors in 2009. He will retain this position but will not be a full-time employee of the company.